Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

The prognosis of malignant gliomas remains poor, with median survival fewer than 20
months and a 5-year survival rate merely 5%. Their primary location in the central nervous …

Zika virus (ZIKV) causes microcephaly by killing neural precursor cells (NPCs) and other
brain cells. ZIKV also displays therapeutic oncolytic activity against glioblastoma (GBM) stem …

In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy.
Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Oxidative stress is induced once the balance of generation and neutralization of reactive
oxygen species (ROS) is broken in the cell, and it plays crucial roles in a variety of natural …

Glioblastoma multiforme (GBM) is a fatal human cancer in part because GBM stem cells are
resistant to therapy and recurrence is inevitable. Previously, we demonstrated Zika virus …

In recent years, it became apparent that cancers either associated with viral infections or
aberrantly expressing endogenous retroviral elements (EREs) are more immunogenic …

Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of
maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that …

Glioblastoma (GBM) is the deadliest primary brain tumor and is generally resistant to
immunotherapy because of severe dysfunction of T cells. Novel treatment options are …